RT Journal Article
T1 Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.
A1 Navarro, Natalia
A1 Molist, Carla
A1 Sansa-Girona, Júlia
A1 Zarzosa, Patricia
A1 Gallo-Oller, Gabriel
A1 Pons, Guillem
A1 Magdaleno, Ainara
A1 Guillén, Gabriela
A1 Hladun, Raquel
A1 Garrido, Marta
A1 Segura, Miguel F
A1 Hontecillas-Prieto, Lourdes
A1 de Álava, Enrique
A1 Ponsati, Berta
A1 Fernández-Carneado, Jimena
A1 Almazán-Moga, Ana
A1 Vallès-Miret, Mariona
A1 Farrera-Sinfreu, Josep
A1 de Toledo, Josep Sánchez
A1 Moreno, Lucas
A1 Gallego, Soledad
A1 Roma, Josep
K1 Cancer
K1 Dissemination
K1 Paediatric cancer
K1 Progression
K1 Solid tumours
AB The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in metastasis and provide evidence demonstrating its essentiality for metastatic dissemination in rhabdomyosarcoma and neuroblastoma. However, the most translational advance of this study is to reveal, for the first time, the possibility of reducing metastasis by pharmacological inhibition of ITGA9 with a synthetic peptide simulating a key interaction domain of ADAM proteins, in experimental metastasis models, not only in childhood cancers but also in a breast cancer model.
YR 2022
FD 2022-10-11
LK http://hdl.handle.net/10668/19542
UL http://hdl.handle.net/10668/19542
LA en
DS RISalud
RD Apr 8, 2025